1 / 93

Natural Health Products in a Global Marketplace: Scientific and Regulatory Perspectives

Natural Health Products in a Global Marketplace: Scientific and Regulatory Perspectives. Joseph M. Betz, Ph.D. Office of Dietary Supplements U.S. National Institutes of Health http://dietary-supplements.info.nih.gov. Overview. Dietary Supplement Overview Introduction to Regulations

ally
Download Presentation

Natural Health Products in a Global Marketplace: Scientific and Regulatory Perspectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Natural Health Products in a Global Marketplace: Scientific and Regulatory Perspectives Joseph M. Betz, Ph.D. Office of Dietary Supplements U.S. National Institutes of Health http://dietary-supplements.info.nih.gov

  2. Overview • Dietary Supplement Overview • Introduction to Regulations • Introduction to National Institutes of Health • Overview of ODS Programs

  3. Dietary Supplements in 2001: $17.7 Billion Minerals Vitamins Herbs / Botanicals Other Supplements Sports Nutrition Source: NBJ, derived from a variety of sources

  4. Top 10 Dietary Supplementsfor 2005 Multivitamins/minerals Calcium B vitamins Vitamin C Glucosamine/Chondroitin Vitamin E Fish oils Coenzyme Q10 Noni juice Probiotics Nutrition Business Journal

  5. Ten Most Common Reasons for Taking Supplements(The Slone Survey) • General health/good for you (16%) • Arthritis (7%) • Memory improvement (6%) • Energy (5%) • Immune booster (5%) • Joints (4%) • Supplement diet (4%) • Sleep aid (3%) • Prostate (3%) • No reason (2%) • All other reasons (45%) JAMA, 2002

  6. Traditional (Herbal) Medicine in the U.S. • Practice of medicine and the licensing of physicians are regulated by the 50 individual states • National laws deal mostly with products • U.S. Food and Drug Administration (FDA)

  7. FD&C Act • Products • Foods, dietary supplements, or drugs based on “intended use” • e.g Psillyium husk can be a food, dietary supplement or drug • Applicable regulations for the category apply • Intended use is ascertained by accompanying labeling claims, advertising materials, or oral or written statements

  8. Botanical Drugs • Intended use to cure, treat, mitigate, etc. • Subject to current drug regulations • Pre-market approval for GRASE • Unique qualities recognized by the FDA • inherently more complex than synthetics • more likely to be components in mixtures • active constituents and activity not always well defined

  9. DSHEA(Dietary Supplement Health and Education Act - 1994) • Amended the FD & C Act • Defined dietary supplements • Established regulatory framework • Food and Drug Administration (FDA) • As foods, not as drugs • Established rules for what a label should contain • Gave FDA authority to write GMP • Called for creation of the Office of Dietary Supplements • Placed it in the Office of the Director at the National Institutes of Health

  10. Dietary Supplement • “...any product (other than tobacco) that contains a vitamin, mineral, herb, or other botanical or amino acid and is intended as a supplement to the diet.” • A concentrate, metabolite, constituent, or combination of the above • Prior to DSHEA, most botanicals treated as food additives or as drugs • Approved, unapproved

  11. Dietary Supplement • Foods, therefore safe by definition • No premarket safety approval except “new dietary ingredients” (75 day notification) • Statements of Nutritional Support (“Structure/Function”) claims permitted • No premarket approval for efficacy required (30 day notification) • Disease claims prohibited • Intended for ingestion • NOT REPRESENTED AS CONVENTIONAL FOOD Guide to Dietary Supplements http://vm.cfsan.fda.gov/~dms/dietsupp.html

  12. New Dietary Ingredients • Not marketed in U.S. prior to 10/15/94 • Not a new ingredient: • If ingredient was “in the food supply… in a form... not chemically altered” • No list of “FDA approved” ingredients • Mfr. Determines whether “new” • notifies FDA 75 d pre-market • Exempt from food additive provisions

  13. Dietary Supplements • 21 CFR Part 111 • Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements; Final Rule • Published June 25, 2007 • http://www.cfsan.fda.gov/~lrd/fr07625a.html

  14. Dietary Supplements • 21 CFR Part 111 • Requires manufacturers to set specifications • Requires manufacturers to test to see if specifications are met using “scientifically valid” methods

  15. General Provisions • CGMP applies to activities associated with • manufacturing • packaging • holding • distributing • Manufacturer needs to comply with requirements applicable to operations performed • contractor needs to comply with applicable requirements and • contracting firm responsible for contractor’s performance

  16. Proposed Requirement Highlights • Personnel • Physical plant internal environment • Equipment and utensils • Production and process controls • quality control unit • master manufacturing & batch production records

  17. Public Law 109–462 • Dietary Supplement and Nonprescription Drug Consumer Protection Act • http://www.fda.gov/opacom/laws/pl109462.html • 22 Dec 2006, took effect Dec 2007 • Mandatory Serious Adverse Event Reporting for OTC drugs and Dietary Supplements • Manufacturer must provide a mechanism for reporting (reports to manufacturer) • Manufacturer must report serious events to FDA

  18. Public Health Security and Bioterrorism Preparedness and Response Act of 2002 • Signed into law June 12, 2002 • Relevant Provision is Title 3: Protecting Safety and Security of Food and Drug Supply. • Title 3 contains 15 sections with relevant provisions to the DS industry.

  19. Homeland Security • SECTION 303: Administrative Detention • FDA may order the detention of foods when credible evidence exists that they present a threat of serious adverse health consequences or death to humans or animals • SECTION 305: Registration of Facilities • Requires that any facility engaged in manufacturing, processing, packaging or holding food for consumption in the U.S. register with the Secretary

  20. Homeland Security • SECTION 414: Maintenance/Inspection of Records • Companies and individuals involved in any aspect of food production must make and keep records • If FDA suspects dangerous adulteration, records must be made available • SECTION 307: Prior Notice of Imported Food Shipments • Require submission of prior notice of arrival providing each of the following: • Identity of: article, manufacturer and shipper, grower, country of origin, country from which article is shipped, port of entry • Articles failing to meet these requirements shall be refused admission to the U.S

  21. The National Institutes of Health

  22. DSHEA and the NIH • DSHEA called for creation of the Office of Dietary Supplements • Placed at the National Institutes of Health in the Office of the Director • Formally established in 1995 • Strategic planning process guided the first few years of its activities

  23. NIH is the Nation’s Medical Research Agency • 27 Institutes and Centers • Total NIH Budget for 2006: $28 billion • Grants, Contracts, Cooperative Agreements • Department of Health & Human Services www.nih.gov

  24. Research • Intramural- “in-house” at Institutes • Extramural • Grants, Cooperative Agreements, Contracts • http://grants.nih.gov/grants/funding/funding.htm • More than 80% of the NIH budget • Subject to competitive review • Investigator-initiated • Request for Application (RFA)

  25. The Primary Function of NIH is to Conduct and Support Medical Research • 65% Basic Research • 25% Translational • 15% Clinical

  26. NIH Funding for Dietary Supplement Research Has Increased Significantly $ Million

  27. THE OFFICE OF DIETARY SUPPLEMENTS

  28. ODS Mission is to Strengthen Knowledge and Understanding of Dietary Supplements • Evaluate Scientific Information • Stimulate and Support Research • Disseminate Research Results • Educate the Public to Foster an Enhanced Quality of Life and Health for U.S. Population Echinacea Echinacea purpurea

  29. Office of Dietary SupplementsFY 2003 $23.0 M

  30. ODS Has a Broad Array of Programs • Co-funding with NIH Institutes • Evidence-Based Reviews • Botanical Research Centers • Training • Analytical Methods and Reference Materials • Communications and Information St. John’s Wort Hypericum perforatum

  31. ODS Activities are Comprehensive and Global • Dietary Supplement Databases • Surveys of Supplement Use • International Collaborations • Workshops, Conferences, Seminars Ginkgo Ginkgo biloba

  32. RESEARCH AGENDA: Grants Co-funded with NIH ICs

  33. ODS Grant “Portfolio” • Growth of ODS co-funded grant portfolio: • 1996: 6 grants initiated, $300,000 • 2002: 39 grants initiated, total of 59 (new and continuing), $9.3 million • 2003: total of 72 grants, $13.5 million • Broad portfolio: basic, clinical, training • Details available on the ODS website

  34. RESEARCH AGENDA: Evidence-Based Review

  35. Evidence-Based Review Program • Systematic review of the literature, with meta-analysis as appropriate, on DS efficacy and safety • In collaboration with the Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center Network • Major reason for conducting these reviews is to assist NIH in the development of research agendas

  36. ODS Evidence-Based Review Program • Chromium and insulin sensitivity* • Ephedra for weight management and athletic performance enhancement* (with NCCAM) • Omega-3 fatty acids for cardiovascular disease prevention* (with NHLBI) and other health indications • Health effects of soy (with NCCAM) • Antioxidant phytochemicals/B vitamins and neurodegenerative diseases*(with NCCAM) • Multivitamins/multiminerals and chronic disease prevention (with OMAR) • Coagulation, diet, and dietary supplements • Health effects of vitamin D (with multiple partners) *Congressional mandate

  37. Evidence • Pre-Clinical • Ecologic • Observational • Cohort • Intervention • RCT

  38. Ephedra Efficacy and Safety • Systematic review: weight management and athletic performance enhancement • All languages, both published and unpublished • Conclusions: • Modest effect on weight in short term and no evidence of effect on athletic performance • Some side effects seen in trials, some serious adverse events filed with FDA and to a major ephedra manufacturer • Released by Secretary of DHHS, Feb 2003 • Shekelle P et al, JAMA 289:1537-1545, 2003 • ODS and NCCAM convened expert panel to recommend research agenda based on review

  39. Evidence-Based Review of Vitamin D in Relation to Bone Health Conducted by University of Ottawa Evidence-Based Practice Centre Funded by NIH Office of Dietary Supplements & Agency for Health Care Research and Quality Available at http://www.ahrq.gov/clinic/tp/vitadtp.htm & the ODS website

  40. Conference Objectives • Evaluate available evidence on the efficacy and safety of vitamin D, using the AHRQ evidence-based review titled, Effectiveness and Safety of Vitamin D in Relation to Bone Healthas the framework. • Identify gaps in knowledge on the efficacy and safety of vitamin D in general and across the life cycle. .

  41. Findings from the Evidence Based Review • Strong evidence that Vitamin D supplementation reduces falls, fractures and bone loss in men and women 60+ y • Not possible to separate the impact of vitamin D from Ca supplementation— typical amounts used were 700-800 IU Vitamin D/d and 500-1,200 mg Ca/d • Sparse data on other subgroups • Difficult to identify a specific blood level of 25(OH) D indicative of optimal bone health in all population subgroups

  42. Health Effects of Omega-3 Fatty Acids • Asthma • Cancer • Cardiovascular Disease • Cardiovascular Disease Risk Factors • Arrhythmogenic Mechanisms • Child and Maternal Health • Cognitive Function • Eye Health • Type II Diabetes, Rheumatoid Arthritis, and Other Diseases • Mental Health • Organ Transplantation

  43. Omega-3 Fatty Acids • 11 reports; 3 EPCs • 9 focused on human studies • 2 focused on animal and in vitro models • Collaborated on methodological elements • Multiple NIH Institutes and Centers • Multiple diseases and risk factors

  44. Omega-3 Fatty Acids Or Photo of Menhaden - Courtesy of National Oceanic and Atmospheric Administration (NOAA)

  45. Omega-3 and Cancer • RAND EPC (MacLean CH, JAMA 295:403, 2006) • Tumor incidence: prospective cohort studies • Clinical outcomes: RCTs • Tumor behavior: animal, cell culture studies

  46. Omega-3 and Tumor Incidence • 19 prospective cohorts, 11 cancers • Breast: 2 significant (1 positive, 1 negative), 5 not significant • Lung: 2 significant (1 positive, 1 negative), 4 not significant • Supported by another systematic review (Hooper L, BMJ 332:752, 2006)

  47. Health Effects of Omega-3 Fatty Acids • Secondary CVD Prevention • Reduces all cause mortality and other CVD outcomes (sudden death, cardiac death, MI) • Primary CVD Prevention • Large, consistent beneficial effect found for serum triglyceride levels • Little or no effect found for other CV risk factors and markers of CVD

More Related